The cAMP-responsive element-binding protein 3-like 2 (CREB3L2), also known as BBF2H7 or OASIS, is a transcription factor belonging to the CREB/ATF family. It is primarily localized in the endoplasmic reticulum (ER) and plays a critical role in the unfolded protein response (UPR) pathway. Under ER stress, CREB3L2 is proteolytically cleaved, releasing its N-terminal domain, which translocates to the nucleus to regulate genes involved in protein folding, secretion, and ER stress adaptation. This mechanism links cellular stress signaling to transcriptional regulation.
Antibodies targeting CREB3L2 are essential tools for studying its expression, activation, and subcellular localization. They are widely used in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to investigate CREB3L2's role in physiological and pathological contexts. Research has implicated CREB3L2 in cancer progression, particularly in sarcomas and breast cancer, where its dysregulation may influence tumor invasiveness and metastasis. Additionally, CREB3L2 variants are associated with genetic disorders like osteogenesis imperfecta, highlighting its importance in connective tissue homeostasis. These antibodies enable the detection of both full-length and cleaved forms, aiding in the study of its activation dynamics. However, specificity validation (e.g., knockout controls) is crucial due to potential cross-reactivity with related CREB3L family members. Overall, CREB3L2 antibodies are vital for unraveling its multifaceted roles in ER stress response and disease mechanisms.